A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B-cell lymphoma in the rituximab era

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

(2016) S. Dubois et al.   CLINICAL CANCER RESEARCH

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas

(2016) Thomas Menter et al.   HUMAN PATHOLOGY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

PD-L1 Status in Refractory Lymphomas

(2016) Semir Vranic et al.   PLoS One

EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment

(2015) A. Nicolae et al.   BLOOD

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

(2015) J. Kiyasu et al.   BLOOD

Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary

(2015) Chi Young Ok et al.   Oncotarget

EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?

(2014) J. Y. Hong et al.   ANNALS OF ONCOLOGY

Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era

(2014) Ai Sato et al.   CANCER SCIENCE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity

(2014) S-H Kuo et al.   Blood Cancer Journal

Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy

(2013) Jae-Sook Ahn et al.   AMERICAN JOURNAL OF HEMATOLOGY

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

(2013) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation

(2012) Santiago Montes-Moreno et al.   MODERN PATHOLOGY

Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan

(2011) Tsutomu Tanaka et al.   ANNALS OF HEMATOLOGY

EBV Positive Mucocutaneous Ulcer—A Study of 26 Cases Associated With Various Sources of Immunosuppression

(2010) Stefan D. Dojcinov et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Epstein–Barr virus as a prognostic factor inde novonodal diffuse large B-cell lymphoma

(2010) Domingo Morales et al.   LEUKEMIA & LYMPHOMA

Translocations Involving the Immunoglobulin Heavy Chain Gene Locus Predict Better Survival in Gastric Diffuse Large B-Cell Lymphoma

(2008) S. Nakamura et al.   CLINICAL CANCER RESEARCH